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Mammographic texture resemblance generalizes
as an independent risk factor for breast cancer
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Abstract
Introduction: Breast density has been established as a major risk factor for breast cancer. We have previously
demonstrated that mammographic texture resemblance (MTR), recognizing the local texture patterns of the
mammogram, is also a risk factor for breast cancer, independent of percent breast density. We examine if these
findings generalize to another population.
Methods: Texture patterns were recorded in digitalized pre-diagnosis (3.7 years) film mammograms of a nested
case–control study within the Dutch screening program (S1) comprising of 245 breast cancers and 250 matched
controls. The patterns were recognized in the same study using cross-validation to form resemblance scores
associated with breast cancer. Texture patterns from S1 were examined in an independent nested case–control
study within the Mayo Mammography Health Study cohort (S2) of 226 cases and 442 matched controls: mammograms
on average 8.5 years prior to diagnosis, risk factor information and percent mammographic density (PD) estimated
using Cumulus were available. MTR scores estimated from S1, S2 and S1 + S2 (the latter two as cross-validations)
were evaluated in S2. MTR scores were analyzed as both quartiles and continuously for association with breast cancer
using odds ratios (OR) and adjusting for known risk factors including age, body mass index (BMI), and hormone usage.
Results: The mean ages of S1 and S2 were 58.0 ± 5.7 years and 55.2 ± 10.5 years, respectively. The MTR scores on S1
showed significant capability to discriminate cancers from controls (area under the operator characteristics curve
(AUC) = 0.63 ± 0.02, P <0.001), which persisted after adjustment for PD. S2 showed an AUC of 0.63, 0.61, and 0.60 based
on PD, MTR scores trained on S2, and MTR scores trained on S1, respectively. When adjusted for PD, MTR scores of S2
trained on S1 showed an association with breast cancer for the highest quartile alone: OR in quartiles of controls as
reference; 1.04 (0.59 to 1.81); 0.95 (0.52 to 1.74); 1.84 (1.10 to 3.07) respectively. The combined continuous model
with both PD and MTR scores based on S1 had an AUC of 0.66 ± 0.03.
Conclusions: The local texture patterns associated with breast cancer risk in S1 were also an independent risk factor
in S2. Additional textures identified in S2 did not significantly improve risk segregation. Hence, the textural patterns
that indicated elevated risk persisted under differences in X-ray technology, population demographics, follow-up time
and geography.
Introduction
Mammographic density [1] has been established as a risk
factor of breast cancer. In large epidemiological studies,
the highest quartile of mammographic density has shown
a four- to sixfold increased risk of breast cancer [2,3] and
a substantial fraction of breast cancers may be attributed
to this risk factor [4]. It has been hypothesized that mam-
mographic density represents the amount or proportion
of fibroglandular tissue present in the breast but the
underlying mechanisms of the density and breast cancer
association are still uncertain [5]. Recent studies also show
that density reductions with tamoxifen use are also
associated with decreased breast cancer risk [6]. Thus,
mammographic density is both an important risk factor
and potential surrogate marker for response to therapy.
Recently, qualifying an objective measure of density,
based on quantitative calibrated imaging, measuring the
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volume percentage of fibroglandular tissue in raw digital
mammograms has attracted attention [7], and been
associated with breast cancer risk factors [8]. However,
several independent studies have shown that also struc-
tural components of the density distribution relate inde-
pendently to breast cancer risk [9-13]. Borrowed from
trabecular bone analysis, the fractal dimension [14], as
well as several other texture measures, has been sug-
gested. However, which visual patterns of dense struc-
tures that are most significantly associated with risk
remains to be determined. The mammographic texture
resemblance (MTR) [10] does not quantify prespecified
properties of the density distribution, but used machine-
learning to recognize density distribution patterns in
mammograms with known outcome, yielding a density-
independent increased breast cancer risk of two- to
sixfold.
The underlying mechanisms of heterogeneity that
relates to risk can be hypothesized to relate to increased
turnover and thereby more disorganized growth of
fibrous tissue. It is, however, not a priori clear how these
disorganized structures will manifest in mammograms
and how and whether these patterns can be separated
from fibroglandular tissue of normal turnover. A very
general approach, recording and recognizing structural
components from mammograms of subjects with known
outcome has shown very promising results [10,11]. The
major problem with such approaches is whether patterns
associated with risk persist through changes of popu-
lation selection, imaging protocol, X-ray technology,
digitalization, and so on.
We examine whether structural components and tex-
tures were associated with breast cancer risk in two inde-
pendent [10] studies from different clinics, geographical
areas, follow-up times, and with somewhat different
demographics.
Methods
Study population
Two samples were included in the current study: Study 1
(S1) from the national Dutch screening program, and
Study 2 (S2) from the Mayo Mammography Health Study
cohort, a screening mammography cohort established at
the Mayo Clinic [15]. S1 was collected by the Radboud
University, Nijmegen. It included mammograms from 125
screen-detected cases, 120 interval-detected cases and 250
matched controls; all from the same screening units
within the biannual Dutch screening program. This cohort
was originally selected for the purpose of studying the
effect of recall rate [16] and subsequently used for study-
ing the potential of MTR as a marker for breast cancer
risk [10]. In accordance with the Helsinki Declaration,
women participating in this program were asked to give
written informed consent for their data to be used for
evaluative purposes. Institutional review board approval
was not required. Mammograms were ascertained from
1999 to 2001, two screening rounds prior to diagnosis.
Only age and mammographic features were available for
this study.
The Mayo Mammography Health Study (MMHS)
cohort at the Mayo Clinic in Rochester, Minnesota (MN)
was established to examine the association of breast dens-
ity with breast cancer [13,15]. The MMHS was approved
by the Mayo Institutional Review Board. From October
2003 to September 2006, all women scheduled for screen-
ing mammography at the Mayo Clinic were invited to
participate. Eligible women were residents of Minnesota,
Iowa or Wisconsin; age 35+; and had no personal history
of breast cancer. A risk factor questionnaire, consent
form, and permission to link to tumor registries were ob-
tained. For this study, incident breast cancer was identified
through 2009 by linkage to the Mayo Clinic and tri-state
cancer registries. A case-cohort of all incident breast can-
cers and 2,300 randomly selected women (the sub-cohort)
were used to examine the association of breast density
and breast cancer using the earliest available film mam-
mograms [15]. For this analysis, we matched 442 controls
from members of the sub-cohort to 226 cases. Controls
from the randomly selected sub-cohort were matched two
to one to cases on age and time from the earliest available
mammogram to study enrollment/diagnosis date.
Mammographic measures
Both studies used digitized film mammograms. For S1,
the right mediolateral view was digitized on a Vidar
scanner (Vidar Systems Corporation, Herndon, VA, USA)
providing an image resolution of approximately 1,500 ×
2,500 pixels on 12-bit grayscale and size 50 × 50 microns.
In S2, four-view mammograms were digitized on the
Array 2905 laser film digitizer (Array Corporation, Roden,
Netherlands) that similarly has 50 micrometer (limiting)
pixel spacing with 12-bit grayscale bit depth.
The breast region was manually outlined as a skin-air
curve and a line separating breast tissue from the
pectoral muscle. The projected area of the breast region
was recorded.
In S1, a trained radiologist estimated percent density
(PD) on the right mediolateral oblique (MLO) view
using a thresholding approach [17] ignoring subsequent
cancer laterality. There was no observed association
between cancers and radiological readings of these
mammograms by 15 screening radiologists certified by
the National Expert and Training Centre for Breast
Cancer Screening [16].
In S2, PD was scored by a trained reader on the
craniocaudal (CC) or top-down views of the contralateral
breast to the cancer (and matched side for controls) using
a similar approach as S1, Cumulus [18]. The reader was
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blinded to cancer outcome in both studies. The MLO view
of the same breast was used for MTR scoring.
The MTR scores [10,19] rely on training data where
features of the local visual appearance of the mammo-
gram are recorded along with the subject’s case–control
status. As in the previous study on S1 [10], each feature
vector contained 40 numbers reflecting the attenuation
variation in the anterior-posterior direction and orthog-
onally at length scales of 1 to 8 mm around one single
point using the Gaussian scale-space 3-jet [20]. MTR
scores are formed by sampling uniformly 20,000 positions
and retrieving the training patches of most alike features
and cumulating their outcome [19]. Examples of mam-
mograms with increasing MTR score for low-, medium-,
and high-density breasts are given in Figure 1, illustrating
the higher large-scale heterogeneity with increasing
MTR score.
The MTR score was estimated on S1 using S1 as train-
ing data, but in a leave-two-subjects-out cross-validation
fashion [10]: when scoring one subject, this subject as
well as one randomly chosen subject of the opposite
case–control status was left out of the training data. This
Low MTR Medium MTR High MTR
Low 
PD
Med
. PD
High 
PD
Figure 1 Mammograms representing each tertile of percent density and mammographic texture resemblance (MTR) scores in S2. High
MTR images seem to have coarser, more large-scale texture.
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methodology maintains the exact same number of cases
and controls in the training set for all subjects scored,
and thereby avoids any unnecessary bias.
MTR on S2 was scored using three different training al-
gorithms: Training 1 (T1) used the S1 study as training
data; Training 2 (T2) used the S2 study in a leave-two-out
fashion as described for S1 above; Training 3 (T3) used
the pooled S1 + S2 study in a leave-two-out fashion. The
scoring using T1 was performed in Copenhagen and was
blinded to outcome in S2. The MTR scores were trans-
ferred back to the Mayo Clinic for statistical analysis.
Subsequently, case/control status was transferred to
Copenhagen and T2 and T3 could be performed.
Projected mammographic breast area was computed
based on the pectoral muscle line and the skin-air
boundary. Inside this region, the distribution (histogram)
of image intensities was recorded.
Statistical analysis
Data presented are expressed as mean ± standard devi-
ation unless otherwise indicated. Group characteristics
were compared using the nonparametric two-sided Wil-
coxon signed rank test. Reported confidence intervals are
based on 95%. All tests were two-sided and considered
significant when P <0.05.
A series of conditional logistic regression models with
breast cancer as the outcome was fitted to each of the
sets of training scores (T1 to T3). These models were
adjusted for potential confounding variables: body mass
index (BMI), menopause status, and postmenopausal
hormone (PMH) use and percent density (PD). Odds
ratios (OR) describe the association of the MTR scores
with breast cancer, both as quartiles based on the con-
trol distribution and per one SD of each measure.
The ability to discriminate case vs. control status was
evaluated as an area under the receiver operator charac-
teristic (ROC) curve (AUC). AUCs were compared using
the Delong test. For S2, AUCs were calculated within
matched sets in order to utilize the matched nature of
the sample. This was done by comparison of predicted
model risk scores for cases and controls within matched
sets and tabulating how often the case is correctly iden-
tified as having a higher risk score. Bootstrapping was
utilized to provide confidence intervals for AUCs in
this case.
Pearson correlation coefficients were used to summarize
the association among different scores and PD measures.
Kolmogorov-Smirnov tests were used to test differences in
distribution of breast area and intensities.
Results
Participants in S1 were older, mean, 58.0 ± 5.7 years,
range (49 to 81), than participants in S2 (mean 55.2 ±
10.5 years, range (30 to 80) years). S2 had a longer time
from mammogram to diagnosis than S1 (mean, 8.6 years,
range (0.1 to 14.6) vs. mean, 3.7 years, range (2.2 to 4.2),
respectively). In S2, controls were well-matched to cases
on the majority of characteristics (Table 1).
The mean projected breast area was significantly
smaller in S1, a mean of 164.8 ± 49.7 cm2 compared to
S2, a mean 168.9 ± 70.4 cm2 (P = 0.0016). The mean
intensities also differed in the two studies, P <0.0001.
Figure 2 shows the cumulative distribution of projected
breast area and image intensities.
As reported previously [10], S1 showed a significantly
(P <0.01) higher PD in the cases (22.3 ± 10.2%) than in
the controls (19.7 ± 11.4%). Stratifying into screen-
detected and interval cancers the density was higher
(P <0.05) in those subsequently diagnosed as interval
cancers (23.3 ± 1.0%) compared to screen-detected
cancers (21.3 ± 0.9%) at the biannual screening visit.
S2 similarly showed that cases had a higher mean
density than controls (22.0 ± 15.4% vs. 18.4 ± 14.7%,
P <0.01).
The association between quartiles of PD and breast
cancer is shown in Table 2. As expected, there were
more cases than controls in the higher quartiles, and
fewer cases than controls in the lower quartiles for both
studies; this is reflected in the ORs in Table 3.
The associations of MTR, for both quartiles and per
SD, with breast cancer from all three training regimes
are shown in Table 3. Adjusting for BMI, menopause,
age and PMH use, all three trainings show similar asso-
ciations between MTR and breast cancer and ability to
discriminate case/control status (AUC 0.60 to 0.63).
Table 1 Characteristics of the cohort selected from the
Mayo Mammography Health Study (S2)
Study 2 characteristics
Variable Control
(N = 442)
Case
(N = 226)
P value
Patient age at date
of mammography
54.8 ± 10.5 55.8 ± 10.6 0.28
Age
50–59, No. (%) 125 (28%) 61 (27%) 0.73
60–69, No. (%) 108 (24%) 58 (26%) 0.73
70+, No. (%) 33 (7%) 22 (10%) 0.31
Body mass index (Kg/m2) 27.9 ± 6.6 27.9 ± 5.5 0.96
Postmenopause, No. (%) 277 (63%) 131 (58%) 0.24
Postmenopausal hormone use
Never, No. (%) 226 (51%) 124 (55%) 0.36
Former, No. (%) 23 (5%) 9 (4%) 0.48
Current, No. (%) 119 (27%) 64 (28%) 0.70
Unknown, No. (%) 74 (17%) 29 (13%) 0.19
Time to diagnosis/enrollment 8.1 ±3.4 8.6 ±3.9 0.09
Breast area (cm2) 168.8 ±72.0 169.0 ±67.2 0.98
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Table 4 shows the correlation of MTR scores and PD.
All training regimes of MTR show very high correlation
(R >0.85, P <0.001) whereas correlation with PD is low
(R <0.25).
Finally, a combined model (Table 3, bottom) including
both PD and the MTR score based on training on the
independent cohort S1 (T1) show a slightly improved
AUC of 0.66 ± 0.03 and a significant association of both
PD and MTR with breast cancer risk. In comparison, a
model including both PD and MTR on S1 yielded an
AUC of 0.66 ± 0.02.
Discussion
In numerous studies, including S1 and S2, PD, adjusted
for age, BMI, and PMH use, has been associated with
breast cancer risk [1-3]. In this and a previous study [10],
the MTR score is also found to be a risk factor for breast
cancer, that is, independent and complementary to the PD
measure. In S2, MTR scores showed similar risk segre-
gation capability, regardless of whether the MTR was
realized, using training data from S1, S2, or a combination
S1 + S2. This invariance to source of training data argues
in favor of the robustness of the MTR score.
We found comparable associations and discrimination
using the MTR in two different populations: the North
American cohort (S2) was younger and had a wider
range of age than the Dutch cohort (S1). As density in
general decreases with age, the visual appearance of
textural patterns may also be hypothesized to change by
age. In fact, it was shown earlier that density invariant tex-
ture patterns may significantly separate randomly selected
groups of 30 women differing five years in age [19]. How-
ever, given that the risk associations and discrimination
did not differ between the MTR training regimes for the
two studies, we may hypothesize that patterns important
to risk are not changing drastically with age.
The mammographic technology also varied between
the two studies, which used different film and digitizers.
This serves as a potential source of noise in the recog-
nition process of textures between studies. In Figure 2,
the projected mammographic area and the intensity dis-
tribution are illustrated and shown to be significantly
different. Notice especially that the intensities vary much
more between studies than between cases and controls
within studies. Hence, the study population and tech-
nology used for imaging make them appear significantly
different. However, even with this variation in technol-
ogy, the texture patterns were recognized across studies
for their association to risk, underscoring the robustness
of this measure.
(a) Cumulative distribution of projected breast
area in S1 (solid) and S2 (dashed), respectively.
(b) Cumulative intensity distribution in
mammograms of controls (solid) and cancers 
(dashed) for S1 (Thick) and S2 (Thin),
respectively.
Figure 2 Distribution of mammographic breast area and mammographic pixel intensity in S1 and S2 respectively.
Table 2 Stratification of subjects from S2 according to
quartiles of controls based on various scores
Score Q1 Q2 Q3 Q4
Percent density Controls 109 (25%) 110 (25%) 110 (25%) 110 (25%)
Cases 34 (15%) 65 (29%) 51 (23%) 76 (34%)
P value 0.004 NS NS 0.002
MTR Controls 111 (25%) 111 (25%) 109 (25%) 111 (25%)
T1 Cases 38 (17%) 51 (23%) 50 (22%) 87 (38%)
P value 0.015 NS NS <0.001
MTR Controls 110 (25%) 111 (25%) 111 (25%) 110 (25%)
T2 Cases 31 (14%) 48 (21%) 66 (29%) 81 (36%)
P value <0.001 NS NS 0.003
MTR Controls 110 (25%) 111 (25%) 112 (25%) 109 (25%)
T3 Cases 35 (15%) 47 (21%) 63 (28%) 81 (36%)
P value 0.005 NS NS 0.002
Mammographic texture resemblance (MTR) scores require training. Numbers
are given for training based on S1 (T1), S2 (T2), and S1 and S2 (T3)
respectively. The latter two are performed in a leave-two-out fashion.
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The North American cohort has a larger projected
breast area than the Dutch cohort. BMI measurements
are present for the North American cohort while BMI
was not recorded in the Dutch cohort. Breast size as cup
size has shown to be inversely related to breast density
measured on a different Dutch population [21], a trend
that does not persist after correction for BMI and waist-
to-hip ratio. Hence it may be interpreted that S1 has a
lower BMI than S2. The density measured as a ratio of
projected dense tissue to the projected breast size is in
general inversely related to BMI, contributed mainly to
the larger breast size whereas the dense area does not
change with BMI [22]. Hence, we may hypothesize that
the textures of dense tissue captured by MTR may
therefore persist over ranges of BMI. This is still to be
tested as BMI was not available on S1.
The differences in percent dense tissue between S1
and S2 may be somewhat explained by the large propor-
tion of interval cancers in S1, the hypothesized variation
in BMI, the differences in age, potential differences in
PMH usage, and the interrater variation.
In S2 (Table 1), cancers and controls do not exhibit
significant differences in the well-known risk factors of
BMI and hormone usage. This may be partially contrib-
uted to by the age matching.
PMH use in the Dutch population was relatively low
in the 1990s in the middle-aged population. Only 13 to
19% were current users with an average duration of two
years [23]. In comparison, the North American cohort
had 28% of current users. The Dutch cohort used for
training (T1) is not necessarily balanced for hormone
use in the cases versus controls. This shows that the
rather dramatic effects PMH use may leave on parenchy-
mal patterns [24,25] are not necessarily those picked up
by the MTR methodology. Actually, those patterns that
recognize combined estrogen and progestin treatment
[25] are not present in different amounts in the controls
and cases in S1 [10].
Time to diagnosis was considerably longer (8.6 years
compared to 3.7 years) in the North American cohort
S2. If patterns are stable and non-modifiable, the longer
time window should only allow for more accurate out-
come estimation, whereas if patterns change temporarily
during the observation window, the longer time window
could potentially contaminate prediction. As prediction
is slightly (but insignificantly so) weakened in S2 one
may hypothesize that texture patterns may potentially
change over time, due to age, hormones, menopause,
diet, and so on. Hence, it may be interesting to study the
temporal variations of texture patterns in the individual.
The MTR shows a slightly weaker (0.61 compared to
0.63) but still significant capability to discriminate cases
from controls in S2 compared to S1. This may be due to
closer matching in S2 taking time interval prior to cancer
into account, and not just age as in S1. In both S1 and S2,
Table 3 Models for case/control status adjusted for body mass index (BMI), menopause age and postmenopausal
hormone (PMH) use
Model AUC OR per one SD OR Q2 OR Q3 OR Q4
Percent density 0.63 1.41 (1.16-1.72) 2.2 (1.3-3.7) 1.8 (1.0-3.1) 2.9 (1.6-5.2)
MTR T1 0.60 1.39 (1.17-1.66) 1.4 (0.8-2.3) 1.3 (0.7-2.2) 2.2 (1.4-3.6)
MTR T2 0.61 1.34 (1.14-1.59) 1.6 (0.9-2.7) 2.2 (1.3-3.9) 2.6 (1.5-4.3)
MTR T3 0.59 1.30 (1.10-1.54) 1.4 (0.8-2.4) 2.0 (1.1-3.7) 2.3 (1.4-3.9)
Percent density 0.66 1.36 (1.11-1.66) 2.2 (1.3-3.7) 1.8 (1.0, 3.2) 3.0 (1.6-5.5)
MTR T1 1.36 (1.13, 1.62) 1.0 (0.6-1.8) 0.9 (0.5-1.7) 1.8 (1.1-3.1)
Area under the receiver operator characteristic (ROC) curve (AUC) and odd ratios (ORs) per standard deviation (SD) are from the continuous model. The quartile
analysis is from the discrete model with 95% confidence intervals. The last row includes the combined percent density (PD) and mammographic texture
resemblance (MTR) T1 model AUC and contribution to OR for each of the parameters. The Model column contains four entities: MTR T1, MTR T2, MTR T3, and the
combined PD and MTR T1 model.
Table 4 Correlation of the percent density and
mammographic texture resemblance (MTR) scores in the
three training regimes on S2
Percent
density
MTR T1 MTR T2 MTR T3
Percent density Rho 1.00 0.03 0.12 0.22
P value 0.44 0.003 <0.0001
N 665 665 665 665
MTR T1 Rho 0.03 1.00 0.98 0.88
P value 0.44 <0.0001 <0.0001
N 665 668 668 668
MTR T2 Rho 0.12 0.98 1.00 0.90
P value 0.003 <0.0001 <0.0001
N 665 668 668 668
MTR T3 Rho 0.22 0.88 0.90 1.00000
P value <0.0001 <0.0001 <0.0001
N 665 668 668 668
Numbers are given for training based on S1 (T1), S2 (T2), and S1 and S2 (T3)
respectively. The latter two are performed in a leave-two-out fashion. Reported
are the Pearson correlation coefficient Rho, the P values of being different
from 0, and N, the numbers of observations on which the estimates are based.
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PD and MTR both persist as risk factors, showing that
texture may carry additional recognizable information.
Measures such as fractal dimension [14] have been re-
lated to genetic status (BRCA1 and BRCA2). The associ-
ations between pixel intensity variance [12], Laws
features, Markovian features, run-length features, Fou-
rier features, wavelet features, and power-law features
were compared on a case–control study by Manduca
et al. [9]. Of these, the fractal dimensions, the Laws
features, and the power-law features are all by design
rotationally symmetric and do not differ for horizontal
and vertical features. The Markovian, run-length, wavelet,
and Fourier features potentially have the power to resolve
anisotropic characteristics of the textures. Manduca et al.
did find larger associations with coarse scale features.
Figure 1 also seems to indicate that high MTR scores
relate to the presence of large (coarse) scale textures.
Manduca did not find significant improvement of the
AUC by introducing any texture into models that included
PD, which was not surprising given the correlation of the
texture measures with PD (|R| = 0.39 to 0.76). The MTR
scores show no or only weak correlation with PD (R = 0.03
to 0.22), and may thereby contribute more information to
future breast cancer. In addition, unlike the texture fea-
tures examined in Manduca et al. above, MTR features
have the capability to distinguish spatially varying features
(the indication of a pattern may vary with its position
within the breast) and to measure aspects that were not
intended for by design, as they are selected based on visual
recognition capability, and not the mathematical design of
features. This could also contribute to the differences in
these two studies.
The cause and appearance of textural features relating
to breast cancer risk is potentially very complex. Tissue
density has been suggested to relate to altered protein
composition and accumulation in the tissue, which may
result in cancer [26]. This local deregulation may lead to
an altered local extracellular matrix (ECM) environment
relating to carcinogenesis [27,28]. This may well be
understood as the components in the ECM not only an-
chor cells in proper spatial patterns, but also play im-
portant parts in regulating cell morphology, function,
and apoptosis [28]. Mammographic density may there-
fore include effects of an altered matrix composition, in
turn associated with carcinogenesis, whereas the tissue
organization (MTR) may provide a score associated with
local disorganization. The biological understanding of this
being independent from matrix composition (density),
may find support in other connective tissues and patholo-
gies [29]. As tissue density and tissue distribution (MTR)
were uncorrelated risk factors, this further supports that
both accumulation and distribution are equally important
for tissue function. Hence, both density and the spatial
layout may contribute to risk assessment.
In fact, all three trainings of the MTR measure are highly
correlated to each other, and at best weakly correlated to
density. Also the MTR is associated with breast cancer,
after adjustment for PD. This verifies the finding [10] that
MTR complements the ability of mammographic density
to discriminate those with and without future breast
cancer.
The conclusions of the studies are limited to the demo-
graphics of the populations, including primary European
populations. Furthermore, S1 was not matched or inclu-
ded risk factors other than age, and mammograms from
the right side were always scored independently of the
laterality [30] of future cancer. Samples including both
pre- and postmenopausal women were analyzed together.
Conclusions
We have shown that the mammographic texture resem-
blance, recorded in one study and examined in an inde-
pendent cohort of different age distribution, geography,
breast size distribution, X-ray and scanner technology, is
a risk factor for breast cancer that is independent of
percent density.
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